PURPOSE: The goal of this work was to evaluate the feasibility and outcome of intensity-modulated arc therapy ± cisplatin (IMAT ± C) followed by hysterectomy for locally advanced cervical cancer. PATIENTS AND METHODS: A total of 30 patients were included in the study. The primary tumour and PET-positive lymph node(s) received a simultaneous integrated boost. Four weeks after IMAT ± C treatment, response was evaluated. Resection consisted of hysterectomy with or without lymphadenectomy. Tumour response, acute and late radiation toxicity, postoperative morbidity and outcome were evaluated. RESULTS: All hysterectomy specimens were macroscopically tumour-free with negative resection margins; pathological complete response was 40%. In 2 patients, one resected lymph node was positive. There was no excess in postoperative morbidity. Apart from two grade 3 hematologic toxicities, no grade 3 or 4 acute radiation toxicity was observed. No grade 3, 1 grade 4 (4%) intestinal, and 4 grade 3 (14%) urinary late toxicities were observed. The 2-year local and regional control rates were 96% and 100%, respectively. The 2-year distant control rate was 92%. Actuarial 2-year progression free survival rate was 89%. Actuarial 1- and 2-year overall survival rates were 96% and 91%, while 3-year overall survival was 84%. CONCLUSION: Surgery after IMAT ± C is feasible with low postoperative morbidity and radiation toxicity. Local, regional, distant control and survival rates are promising.
PURPOSE: The goal of this work was to evaluate the feasibility and outcome of intensity-modulated arc therapy ± cisplatin (IMAT ± C) followed by hysterectomy for locally advanced cervical cancer. PATIENTS AND METHODS: A total of 30 patients were included in the study. The primary tumour and PET-positive lymph node(s) received a simultaneous integrated boost. Four weeks after IMAT ± C treatment, response was evaluated. Resection consisted of hysterectomy with or without lymphadenectomy. Tumour response, acute and late radiation toxicity, postoperative morbidity and outcome were evaluated. RESULTS: All hysterectomy specimens were macroscopically tumour-free with negative resection margins; pathological complete response was 40%. In 2 patients, one resected lymph node was positive. There was no excess in postoperative morbidity. Apart from two grade 3 hematologic toxicities, no grade 3 or 4 acute radiation toxicity was observed. No grade 3, 1 grade 4 (4%) intestinal, and 4 grade 3 (14%) urinary late toxicities were observed. The 2-year local and regional control rates were 96% and 100%, respectively. The 2-year distant control rate was 92%. Actuarial 2-year progression free survival rate was 89%. Actuarial 1- and 2-year overall survival rates were 96% and 91%, while 3-year overall survival was 84%. CONCLUSION: Surgery after IMAT ± C is feasible with low postoperative morbidity and radiation toxicity. Local, regional, distant control and survival rates are promising.
Authors: Wim Duthoy; Werner De Gersem; Koen Vergote; Tom Boterberg; Cristina Derie; Peter Smeets; Carlos De Wagter; Wilfried De Neve Journal: Int J Radiat Oncol Biol Phys Date: 2004-11-01 Impact factor: 7.038
Authors: Eric E K Yeoh; Robert J Fraser; Roz E McGowan; Rochelle J Botten; Addolorata C Di Matteo; Daniel E Roos; Michael G Penniment; Martin F Borg Journal: Int J Radiat Oncol Biol Phys Date: 2003-03-15 Impact factor: 7.038
Authors: John M Kirwan; Paul Symonds; John A Green; Jayne Tierney; Mandy Collingwood; Christopher J Williams Journal: Radiother Oncol Date: 2003-09 Impact factor: 6.280
Authors: Richard Pötter; Johannes Dimopoulos; Petra Georg; Stefan Lang; Claudia Waldhäusl; Natascha Wachter-Gerstner; Hajo Weitmann; Alexander Reinthaller; Tomas Hendrik Knocke; Stefan Wachter; Christian Kirisits Journal: Radiother Oncol Date: 2007-05 Impact factor: 6.280
Authors: Valérie Fonteyne; Wilfried De Neve; Geert Villeirs; Carlos De Wagter; Gert De Meerleer Journal: Radiother Oncol Date: 2007-08-10 Impact factor: 6.280
Authors: Matthew Chan; Robert Olson; Vincent Lapointe; Jeremy Hamm; Francois Bachand; Caroline Holloway; Christina Parsons; Peter Lim Journal: Curr Oncol Date: 2022-05-05 Impact factor: 3.109
Authors: Karen Couvreur; Eline Naert; Emiel De Jaeghere; Philippe Tummers; Amin Makar; Pieter De Visschere; Mieke Van Bockstal; Jo Van Dorpe; Wilfried De Neve; Hannelore Denys; Katrien Vandecasteele Journal: BMC Cancer Date: 2018-11-12 Impact factor: 4.430
Authors: Katrien Vandecasteele; Philippe Tummers; Mieke Van Bockstal; Pieter De Visschere; Tom Vercauteren; Werner De Gersem; Hannelore Denys; Eline Naert; Amin Makar; Wilfried De Neve Journal: BMC Cancer Date: 2018-09-17 Impact factor: 4.430